News
Lilly scores against Novo Nordisk in weight loss contest
There’s no data from a head-to-head trial directly comparing Eli …
19708 items found
Oncology
News
Lilly swoops on Morphic to claim IBD drug candidate
Eli Lilly has bolstered its inflammatory bowel disease (IBD) pipeline …
News
Could Spain’s Grifols be heading for de-listing?
The family that owns Spanish drugmaker Grifols and private equity …
News
As IARC uprates talc cancer risk, will J&J be affected?
The International Agency for Research on Cancer (IARC) has published …
News
Myricx raises £90m after pivot to ADCs for cancer
UK biotech Myricx Bio has tapped into the red-hot interest among …
Patients
Healthcare report finds declining public trust in institutions
There are few things more important than health, but a recent report …
News
Study finds GLP-1 drugs may cut obesity-related cancers
Potentially adding to a lengthening list of positive health benefits …
News
Four drugmakers found to have breached ABPI code
Novartis, Pfizer, Otsuka and Novo Nordisk have been called out by the …
Patients
Labour, the NHS, and life sciences: Partnerships and people
The United Kingdom this morning woke to landslide poll results: …
News
NHS will take more than one term to fix, says Streeting
While the headlines are all about the Labour landslide in the UK …
Oncology
Single-cell multi-omics and oncological potential
Just like people, no two cancer cells are alike. And now, scientists …
News
Starboard spells out its concerns with Pfizer's direction
Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as
Sales & Marketing
Enabling site success: Key insights to reducing burden and i...
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Digital
Access to genomic surveillance: Open science and public heal...
The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens.
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
BIO-Europe's 30th Anniversary Landmark Event in Stockholm
BIO-Europe™ celebrates 30 years of facilitating partnerships this Fall. In 1994, BIO-Europe launched with the mission to drive biotech innovation and
R&D
Partner Content
8th Dermatology Drug Development Summit
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
